Expert Insights

Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19

Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19

Experts at MMS have reviewed COVID-19 guidance documents and taken into account the current state of clinical research globally to ensure our services align with these new challenges, whether those sponsors be virtual or large firms with treatments for common illnesses or rare conditions. What has been identified in this whitepaper are key areas of change faced by the industry.

Unprecedented does not have to mean unprepared: Business Continuity Planning

Unprecedented does not have to mean unprepared: Business Continuity Planning

by Jessica Alamdari, April 3, 2020
During these unprecedented times, many businesses are struggling to continue business as usual while the world is rapidly changing around them; however, certain businesses continue to thrive. Throughout this COVID-19 pandemic, companies like MMS, among other leaders in the pharmaceutical industry, are not only carrying out typical day-to-day business operations, but they are well-positioned to offer additional support to companies unable to adapt.

Pharmaceutical Industry News Roundup: February 2020

Pharmaceutical Industry News Roundup: February 2020

by Staff writer
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. February’s news includes coronavirus vaccine development, saving 7 million lives from cancer, and more.

The New Roaring 20s: 12 Experts Provide Pharmaceutical Insights for the Decade Ahead

The New Roaring 20s: 12 Experts Provide Pharmaceutical Insights for the Decade Ahead

by Aaron Robert, February 7, 2020
The pharmaceutical industry—and healthcare in general—are in constant stages of innovation. According to the International Federation of Pharmaceutical Manufacturers & Associations, the number of new chemical or biological entities launched on the world market stood at 226 from the years 2011 to 2015, a 35 percent increase from the decade prior.

Webinar: The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

Webinar: The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

by MMS Holdings and MichBio.org
This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in drug development, from the perspective of a clinical trial programmer/data analyst. We will discuss the potential opportunities that can generate RWD to improve the safety, efficiency, and quality in a clinical paradigm.

Pharmaceutical Industry News Roundup: September 2019

Pharmaceutical Industry News Roundup: September 2019

Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection of top stories to keep an eye on in September 2019: FDA Developing Guidance on Real-World Data Quality Issues, Officials Say.

 

6880 Commerce Blvd.
Canton, MI 48187 USA
734.245.0310 T
734.245.0320 F

Email Us

LinkedIn

 

Facebook

Learn more about working with MMS

1 + 8 =

© MMS Holdings Inc. All rights reserved. Privacy Policy